iBio (IBIO) Accumulated Expenses (2011 - 2026)

iBio (IBIO) has reported Accumulated Expenses for 16 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 34.87% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 34.87% YoY), while the FY2025 annual figure was $1.3 million, down 33.68% from the prior year.
• Accumulated Expenses grew to $1.8 million in Q1 2026 per IBIO's latest filing, from $1.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.0 million in Q4 2022 and bottomed at $183000.0 in Q2 2023.
• Historically, Accumulated Expenses has averaged $2.4 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses sank 94.03% — and 2024, when it soared 1008.2%.
• iBio's Accumulated Expenses stood at $5.0 million in 2022, then dropped by 24.88% to $3.8 million in 2023, then tumbled by 51.16% to $1.8 million in 2024, then dropped by 13.95% to $1.6 million in 2025, then rose by 13.17% to $1.8 million in 2026.
• Business Quant data shows IBIO's Accumulated Expenses at $1.8 million in Q1 2026, $1.6 million in Q4 2025, and $850000.0 in Q3 2025.